 Taxoids
"Taxoids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
| Descriptor ID |
D043823
|
| MeSH Number(s) |
D02.455.426.392.368.242.888 D02.455.849.291.850
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Taxoids".
Below are MeSH descriptors whose meaning is more specific than "Taxoids".
This graph shows the total number of publications written about "Taxoids" by people in this website by year, and whether "Taxoids" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 2003 | 3 | 0 | 3 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 1 | 2 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Taxoids" by people in Profiles.
-
Wei XX, Ko EC, Ryan CJ. Treatment strategies in low-volume metastatic castration-resistant prostate cancer. Curr Opin Urol. 2017 Nov; 27(6):596-603.
-
Ciccarese C, Santoni M, Massari F. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. N Engl J Med. 2016 01 21; 374(3):286.
-
Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F. AR-V7 and prostate cancer: The watershed for treatment selection? Cancer Treat Rev. 2016 Feb; 43:27-35.
-
Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep; 16(5):340-7.
-
Caffo O, De Giorgi U, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Macrini S, Messina C, Giordano M, Alesini D, Zustovich F, Fraccon AP, Vicario G, Conteduca V, Maines F, Galligioni E. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. BJU Int. 2015 May; 115(5):764-71.
-
Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M, Yardley DA. Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2012 Oct; 12(5):322-30.
-
Patil RA, Kolewe ME, Normanly J, Walker EL, Roberts SC. Contribution of taxane biosynthetic pathway gene expression to observed variability in paclitaxel accumulation in Taxus suspension cultures. Biotechnol J. 2012 Mar; 7(3):418-27.
-
De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010 Jan 01; 28(1):149-53.
-
Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008 Dec 10; 26(35):5755-60.
-
Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, Leichman CG. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Aug 20; 26(24):3979-86.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|